Eton Pharmaceuticals (NASDAQ:ETON) Stock Jumps 5.4% – What’s Next?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) shares rose 5.4% during mid-day trading on Friday. The stock traded as high as $64.34 and last traded at $64.79. 235,189 shares were traded during trading, a decline of 49% from the average session volume of 461,895 shares. The stock had previously closed at $61.45.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ETON. Weiss Ratings raised shares of Eton Pharmaceuticals from a “hold (c)” rating to a “buy (b-)” rating in a report on Monday. B. Riley Financial raised their price target on shares of Eton Pharmaceuticals from $70.00 to $81.00 and gave the stock a “buy” rating in a research report on Tuesday. Canaccord Genuity Group lifted their price target on shares of Eton Pharmaceuticals from $68.00 to $80.00 and gave the company a “buy” rating in a report on Friday, November 6th. Craig Hallum reaffirmed a “buy” rating and set a $78.00 price objective on shares of Eton Pharmaceuticals in a research report on Thursday, October 15th. Finally, Zacks Research lowered shares of Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Eton Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $79.75.

Eton Pharmaceuticals Stock Up 3.3%

The firm has a market cap of $1.83 billion, a price-to-earnings ratio of 42.04 and a beta of 0.89. The stock has a 50-day moving average of $55.18 and a 200-day moving average of $37.47. The company has a current ratio of 1.79, a quick ratio of 1.58 and a debt-to-equity ratio of 0.13.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its earnings results on Thursday, November 5th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.19. The firm had revenue of $57.93 million for the quarter, compared to analyst estimates of $41.98 million. Eton Pharmaceuticals had a return on equity of 104.82% and a net margin of 35.35%. As a group, sell-side analysts forecast that Eton Pharmaceuticals, Inc. will post 1.54 EPS for the current fiscal year.

Insider Activity at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, insider Ipek Erdogan-Trinkaus sold 3,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $67.41, for a total value of $235,935.00. Following the sale, the insider owned 4,081 shares in the company, valued at approximately $275,100.21. This trade represents a 46.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Paul V. Maier sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the completion of the sale, the director owned 59,745 shares in the company, valued at $3,529,137.15. The trade was a 45.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 82,666 shares of company stock worth $5,045,607 in the last ninety days. 16.49% of the stock is owned by insiders.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. EcoR1 Capital LLC increased its position in Eton Pharmaceuticals by 7.0% in the 1st quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock valued at $53,603,000 after acquiring an additional 141,394 shares during the period. BlackRock Inc. bought a new stake in Eton Pharmaceuticals during the 2nd quarter valued at $68,629,000. Nantahala Capital Management LLC acquired a new position in Eton Pharmaceuticals during the 2nd quarter worth $42,569,426. Pillsbury Lake Capital LLC acquired a new position in Eton Pharmaceuticals during the 2nd quarter worth $14,015,083. Finally, Panoramic Capital LLC bought a new position in shares of Eton Pharmaceuticals in the second quarter worth $7,537,000. 27.86% of the stock is owned by institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited treatment options. Its work includes bringing new medicines and reformulated or otherwise specialized drug products to market. The company’s products include Alkindi Sprinkle, a hydrocortisone granule formulation used to treat adrenal insufficiency, and Eprontia, an oral solution of topiramate used to treat certain seizure disorders and prevent migraines.